

Enhancements to the AIR functionality of Influenza Vaccines (Australian Government Department of Health and Aged Care)

In preparation for the 2023 Influenza season, the following enhancements will be made to the Australian Immunisation Register (AIR) on 11 February 2023:

Addition of new Influenza vaccines

To enable better monitoring and reporting of influenza vaccines funded under the National Immunisation Program (NIP), the following vaccine names will be added to the AIR.

Addition of new Influenza vaccines

Vaccine Brand Name	Vaccine Code
Afluria Quad (NIP)	AFLQUA
Afluria Quad (Non-NIP)	QUADAF
Fluarix Tetra (NIP)	FLXTET
Fluarix Tetra (Non-NIP)	ARXFLU

This change will enable vaccination providers to select whether an influenza vaccine is funded under the NIP or purchased on the private market. When reporting to the AIR, vaccination providers should select the relevant vaccine name i.e. (NIP) for NIP funded vaccines and (Non-NIP) for privately purchased vaccines. For individuals, only the vaccine brand name will display on their Immunisation History Statement. For example, Afluria Quad (NIP) will display as “Afluria Quad”.

These new vaccine names will be available to report to the AIR using clinical software, however, if these vaccines do not appear, we recommend vaccination providers contact their software provider in the first instance. Alternatively, vaccination providers can report the vaccine to the AIR using the [AIR site](#).

Updates to existing Influenza vaccines

To improve the data quality and reporting of influenza vaccines, the AIR will be updated to prevent the reporting of historical vaccine brands that are no longer registered or available for use in Australia. Please see below:

Removal of below Influenza vaccines

Vaccine Brand Name	Vaccine Code
Afluria Quad	AFLR
Fluvax	FLUVAX
Vaxigrip	VAXGRP
Fluarix	FLRIX
Fluarix Tetra	FLUTET
FluQuadri Junior	FQDJN
Fluvirin	FLVRN
Panvax	PANVAX
Influvac	INFLUV
Agrippal	AGRPAL
Vaxigrip Junior	VGRJNR
Fluvax Junior	FVXJNR
Fluad	FLUAD
Fluzone High-Dose	FLUHID

Please note:

Vaccination providers will still be able to report these vaccines if they were administered prior to 11 February 2023. Influenza vaccines reported to the AIR prior to 11 February 2023 will remain recorded on the AIR and display on individuals’ vaccination evidence.

In instances where an individual has been vaccinated (i.e., overseas) and the vaccine brand is not available to report to the AIR, vaccination providers can report it as a generic vaccine brand, for example ‘Generic Influenza’. This ensures that individuals have a complete AIR record and can provide evidence of vaccination for education, employment, or travel purposes.

It is mandatory under the *Australian Immunisation Register Act 2015*, for vaccination providers to report all Influenza vaccinations administered on, or after, 1 March 2021.

Reporting timely, high quality and accurate vaccination information ensures that the AIR contains a complete and reliable dataset to enable the monitoring of immunisation coverage and administration.

The Department of Health and Aged Care will continue to work with Services Australia to help software developers and vaccination providers meet their reporting obligations.

Keep up to date with the latest information on the [AAPM website](#)



Australian Association of Practice Management
Level 1/60 Lothian Street, North Melbourne, Vic 3051
T 1800 196 000

Our Vision: Practice Management to be universally recognised and valued at the centre of effective healthcare systems and sustainable businesses for optimal patient outcomes.

You are receiving this email because you are a valued AAPM Member or have signed up to the AAPM mailing list.

No longer wish to receive these emails? [\[\[UNSUBSCRIBE\]\]](#)

Copyright © 2023 Australian Association of Practice Management, All rights reserved.